ArticleNeural plasticity2026
Ginsenoside Rg1 Improves PTSD-Like Sleep Disturbances in Male Mice: Involvement of NLRP3-Related Inflammatory and Apoptotic Pathways.
Article in Neural plasticity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Sleep disturbances (SD) are not merely symptoms of posttraumatic stress disorder (PTSD), but also amplify and perpetuate all other PTSD phenotypes. Ginsenoside Rg1 is extensively applied in managing neuropsychiatric diseases. Nevertheless, its impact on PTSD-like SD and mechanisms remain largely unknown. In this study, the PTSD model in mice was produced using single-prolonged stress (SPS) and the improvement effect of ginsenoside Rg1 on PTSD-like behavior in mice, especially the sleep-wake phase was detected. The potential targets and signaling pathways of ginsenoside Rg1 as an intervention for treatment of PTSD with sleep disturbances (PTSD-SD) were predicted using bioinformatics analysis. Thereafter, in vivo experiments were further used to verify the results. Our data showed that 14 days after SPS, the sleep architecture of mice was significantly disturbed, while ginsenoside Rg1 could treat PTSD-like SD in SPS mice. The results of bioinformatics analysis suggested that NLRP-related pathways and apoptosis may be the key factors for ginsenoside Rg1 to treat PTSD-like sleep disturbances. Meanwhile, animal experiments also showed that the NLRP3 inflammasome, oxidative stress and apoptosis-related markers were abnormally expressed in the hippocampus of SPS mice, but the administration of ginsenoside Rg1 could counteract the dysregulated expression of the above proteins in SPS mice. Finally, the results of docking revealed that ginsenoside Rg1 had favorable binding affinity with verified targets including NF-κB, NLRP3, ASC, GFAP, HO-1, and cleaved caspase-3. Collectively, ginsenoside Rg1 is effective to prevent PTSD-like SD, likely by regulating systemic comprehensive responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.